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THE MOLECULAR INTERACTION BETWEEN TYPE II DIABETES AND 
ALZHEIMER’S DISEASE THROUGH CROSS-SEEDING OF PROTEIN 
MISFOLDING 
George Edwards III, B.S. 
Thesis Advisor: Claudio Soto, Ph.D. 
With the population of the world aging, the prominence of diseases such as Type II 
Diabetes (T2D) and Alzheimer’s disease (AD) are on the rise. In addition, patients with 
T2D have an increased risk of developing AD compared to age-matched individuals, 
and the number of AD patients with T2D is higher than among aged-matched non-AD 
patients. AD is a chronic and progressive dementia characterized by amyloid-beta (Aβ) 
plaques, neurofibrillary tangles (NFTs), neuronal loss, brain inflammation, and 
cognitive impairment. T2D involves the dysfunctional use of pancreatic insulin by the 
body resulting in insulin resistance, hyperglycemia, hyperinsulinemia, pancreatic beta 
cell (β-cell) death, and other complications. T2D and AD are considered protein 
misfolding disorders (PMDs). PMDs are characterized by the presence of misfolded 
protein aggregates, such as in T2D pancreas (islet amyloid polypeptide - IAPP) and in 
AD brain (amyloid– Aβ) of affected individuals. The misfolding and accumulation of 
these proteins follows a seeding-nucleation model where misfolded soluble oligomers 
act as nuclei to propagate misfolding by recruiting other native proteins. Cross-seeding 
occurs when oligomers composed by one protein seed the aggregation of a different 
protein. Our hypothesis is that the pathological interactions between T2D and AD may 
in part occur through cross-seeding of protein misfolding. To test this hypothesis, we 
examined how each respective aggregate (Aβ or IAPP) affects the disparate disease 
pathology through in vitro and in vivo studies. Assaying Aβ aggregates influence on 
T2D pathology, IAPP
+/+
/APPSwe
+/-
 double transgenic (DTg) mice exhibited exacerbated 
vi 
 
T2D-like pathology as seen in elevated hyperglycemia compared to controls; in 
addition, IAPP levels in the pancreas are highest compared to controls. Moreover, 
IAPP
+/+
/APPSwe
+/-
 animals demonstrate abundant plaque formation and greater plaque 
density in cortical and hippocampal areas in comparison to controls. Indeed, 
IAPP
+/+
/APPSwe
+/-
 exhibit a colocalization of both misfolded proteins in cerebral plaques 
suggesting IAPP may directly interact with Aβ and aggravate AD pathology. In 
conclusion, these studies suggest that cross-seeding between IAPP and Aβ may occur, 
and that these protein aggregates exacerbate and accelerate disease pathology, 
respectively. Further mechanistic studies are necessary to determine how these two 
proteins interact and aggravate both pancreatic and brain pathologies. 
  
vii 
 
Table of Contents 
 
Approval Signatures…………………….……………………………………...............i 
Title Page………………………………………….………………………………........ii 
Dedication.......................................................................................................................iii 
Acknowledgements………………………………………………..………...……........iv 
Abstract……………………………………………………….…………...………........v 
Table of Contents……………………………………….……………………….……vii 
List of Figures…………………………………………………………………..……...xi 
Abbreviations………………………………………………………………….….......xiii 
CHAPTER 1. Introduction..…….……………………………………….………….....1 
Type II Diabetes and Alzheimer’s disease Prevalence and Characteristics……………..2 
Misfolded Protein Aggregates in Type II Diabetes and Alzheimer’s disease………….. 6 
The Seeding-Nucleation and Cross-Seeding Model…………………………………...11 
Hypothesis…..................................................................................................................14 
CHAPTER 2. Analyze cross-seeding interaction between Aβ and IAPP utilizing in 
vitro studies….................................................................................................................15 
Rationale…………………………………………………………………………….…16 
Results………………………………………………………………………………….18 
In vitro IAPP Heterologous Cross-Seeding Accelerates Aβ aggregation….......18 
Aβ Heterologous Cross-Seeding Increases IAPP aggregation In vitro…….......20 
viii 
 
Summary………………………………………………………………………………23 
CHAPTER 3. Determine the influence of Aβ aggregated “seeds” on T2D pathology in 
a double transgenic mouse model …………………………….…………………….....24 
Rationale……………………………………………………………………………….25 
Results………………………………………………………………………………….26 
DTg IAPP+/+/APPSwe
+/- Demonstrate Accentuated Blood Glucose Levels.........26 
DTg IAPP+/+/APPSwe
+/- Exhibit Elevated IAPP Burden Levels……………......28 
 Heterozygous IAPP+/-/APPSwe
+/- Mice Have T2D-like Pathology…………......30 
Summary………………………………………………………………………………32 
CHAPTER 4. Evaluate the influence of IAPP aggregated “seeds” on AD pathology 
in a double transgenic mouse model............................................................................33 
Rationale……………………………………………………………………………….34 
Results………………………………………………………………………………….35 
DTg IAPP+/+/APPSwe
+/- Exhibit Increased Cortical and Hippocampal Aβ Burden 
Levels…………………………………………………………………..............35 
DTg IAPP+/+/APPSwe
+/- Reveal Increased Cortical and Hippocampal Aβ Density 
Levels………………………………………………………………..................39 
Colocalization of IAPP and Aβ in Cerebral Plaques in the DTg 
IAPP+/+/APPSwe
+/-………………………………………………………...…......42 
Summary……………………………………………………………………………....46 
CHAPTER 5. Discussion…….….……………………………………………………47 
ix 
 
Cross-seeding Evidences in T2D and AD……………………………………………..48 
Relevance of Study for Novel Therapeutics…………………………………………...50 
CHAPTER 6. Conclusion and Future Directions……………….….………….……52 
Conclusions……………………………………………………………………………53 
Future Directions………………………………………………………………….......55 
Characterization and Quantification of In Vitro Cross-seeding…………..........55 
Biochemical Quantification of Amyloids in Brain and Pancreas………….......55 
Exogenous Cross-Seeding of Aβ on T2D and IAPP on AD………………......56 
CHAPTER 7. Materials and Methods...………………………………….………….61 
In Vitro Aβ-42 and IAPP Preparation and Aggregation………………………..61 
In vitro Aβ and IAPP Oligomer Preparation…………………………………...64 
Animal Models…………………………………………………………………64 
Generation of STZ Injected APPSwe
+/-
 (T1D Control)………………………….64 
Immunohistochemistry (IHC)………………………………………………….66 
Image Analysis…………………………………………………………………66 
Statistical Analysis……………………………………………………………..68 
CHAPTER 8. Appendix………………………………….…………………………...69 
Bibliography……………….………………………………………………………......70 
x 
 
Vita………………………………………………………………………….……….....79 
 
 
  
  
xi 
 
List of Figures 
Figure 1: Protein Misfolding Disorders (permission acquired)………………………..........5 
Figure 2: Formation of IAPP………………………………………………………….8 
Figure 3: Formation of Aβ through APP Cleavage………………………………….9 
Figure 4. Comparison of Structures of Aβ and IAPP(permission acquired)………………11 
Figure 5: The Cross-Seeding Model………………………………………………....13 
Figure 6: In vitro Aβ Aggregation is Enhanced by Adding Heterologous IAPP 
Seeds…………………………………………………………………………………...20 
Figure 7: In vitro IAPP Aggregation is Enhanced by the Addition of Aβ Seeds….22 
Figure 8: DTg IAPP
+/+
/APPSwe
+/-
 Demonstrate Significantly Elevated BGLs……..27 
Figure 9: DTg IAPP
+/+
/APPSwe
+/- 
Exhibit Elevated IAPP Burden Levels……….....29 
Figure 10: DTg IAPP
+/+
/APPSwe
+/- 
Exhibit Increased IAPP Burden Levels….........30 
Figure 11: DTg IAPP
+/+
/APPSwe
+/- Mice Display Higher Aβ Immunopositive 
Plaques in the Brain………………………………………………………………......36 
Figure 12: DTg IAPP
+/+
/APPSwe
+/- Exhibit Increased Cortical and Hippocampal Aβ 
Burden Levels……………………………………………………………………........38 
Figure 13: DTg IAPP
+/+
/APPSwe
+/- Reveal Increased Cortical and Hippocampal Aβ 
Density Levels…………………………………………………………………………41 
xii 
 
Figure 14: Colocalization of IAPP and Aβ in Cerebral Plaques in the DTg 
IAPP
+/+
/APPSwe
+/-…………………………………………………………..………….44 
Figure 15: Pancreatic IAPP Burden Correlates with Cortical Aβ Burden in the 
DTg IAPP
+/+
/APPSwe
+/- 
and Het DTg IAPP
+/-
/APPSwe
+/-……………………………..45 
Figure 16: Exogenous Cross-seeding of Aβ on T2D………………………………...58 
Figure 17: Exogenous Cross-seeding of IAPP on AD and Aβ Aggregates………...60 
  
xiii 
 
Abbreviations 
Aβ – Amyloid-Beta 
AD – Alzheimer’s disease 
ADDLs – Amyloid-Beta Derived Diffusible Ligands  
AGEs – Advance Glycation End Products 
Akt – Protein Kinase B 
ALS – Amyotrophic Lateral Sclerosis 
APP – Amyloid Precursor Protein 
ApoE – Apolipoprotein E 
β-cell – Beta Cell 
BACE1 – Beta-secretase 1 
BBB - Blood-brain barrier 
BCA – Bichinchoninic Acid Assay 
BGLs – Blood Glucose Levels 
C99 – C-terminal 99-amino acid fragment 
CSF – Cerebrospinal Fluid 
DTg – Double Transgenic 
xiv 
 
EDTA - Ethylenediaminetertraacetic acid 
ELISA - Enzyme-linked immunosorbent assay  
FTD – Frontotemporal Dementia 
Het – Heterozygous 
huIAPP – Human Islet Amyloid Polypeptide or Amylin 
IAPP – Islet Amyloid Polypeptide or Amylin 
IHC – Immunohistochemistry 
I.C. – Intra-cerebral 
I.P. – Intra-peritoneal 
LTP – Long Term Potentiation 
MCI - Mild cognitive impairment 
NFTs – Neurofibrillary Tangles 
PAM – Peptidylglycine Alpha-Amidating Monooxygenase  
PD – Parkinson’s disease 
PMDs – Protein Misfolding Disorders 
ProIAPP – Proislet Amyloid Polypeptide 
PC1/3 – Proprotein Convertase 1/3 
xv 
 
PC2 – Proprotein Convertase 2 
PrPSc - Misfolded prion protein  
PS1 – Presenilin 1 
PS2 – Presenilin 2 
RT-PCR – Real Time-Polymerase Chain Reaction 
S.E.M. - Standard Error of the Mean 
ThT – Thioflavin T 
TEM – Transmission Electron Microscopy 
TSEs – Transmissible Spongiform Encephalopathies 
T1D – Type I Diabetes 
T2D – Type II Diabetes  
1 
 
 
 
 
 
 
 
 
 
CHAPTER 1 
Introduction 
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Type II Diabetes and Alzheimer’s disease Prevalence and Characteristics. 
As the life expectancy of the population increases, as well as individuals living 
unhealthy lifestyles so too does the prevalence of age-related diseases such as Type II 
Diabetes (T2D) and Alzheimer’s disease (AD). It is estimated that 25.8 million 
American individuals have diabetes – 90-95% being T2D (1). In addition, the total 
projected cost of diabetes in 2007 was 218 billion dollars (1). It is expected that 5.4 
million individuals currently live with AD; moreover, the socioeconomic burden is 
tremendous costing $200 billion dollars (2). In addition, both diseases present 
complications to effectively diagnose individuals in that nothing is really offered for 
AD, as well as there are T2D affected individuals that go undiagnosed. By 2050, it is 
projected that the prevalence of diabetes and AD will double or even triple (1-2).  
Though these statistics are malicious enough already, recent research posits that having 
T2D can 2-5 fold increase the risk of AD (3-6); moreover, the number of T2D among 
AD patients is significantly augmented in comparison to age-matched non-AD controls 
(4, 7-8).  
Type II Diabetes involves the dysfunctional use of pancreatic insulin by the 
body resulting in insulin resistance, hyperglycemia, hyperinsulinemia, pancreatic β-cell 
death, and other complications. Some of these diabetic complications can ultimately 
lead to cardiovascular disease, kidney disease, neuropathy, and diabetic retinopathy (9-
10). Unlike Type I Diabetes (T1D), insulin is produced, but the body does not use it 
effectively. Insulin is an important hormone, and if the availability is insufficient, 
insulin is faulty, or the cell’s response is defective (referring to sensitivity), then glucose 
will not be absorbed or stored properly by the cells. Thus, the net effect is high blood 
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glucose levels, irregular protein synthesis, and a number of other metabolic 
derangements. Intriguingly, in up to 96% of T2D patients, is the aggregation of an 
amyloidogenic species called islet amyloid polypeptide (IAPP) (3-7, 11) which is 
thought to have deleterious effects to the β-cells (12), yet it is unknown if IAPP is either 
a cause or an effect of the disease (13). 
Characterized by Alois Alzheimer around 1905 from a patient named Auguste 
Deter, Alzheimer’s disease is an age-related, chronic and progressive dementia 
characterized by extracellular amyloid-beta (Aβ) plaques, intracellular neurofibrillary 
tangles (NFTs), neuronal loss, brain inflammation, and cognitive impairment. Some of 
the known risk factors include: age (affecting 65 and up), the female gender, the APOE 
allele, and oxidative stress (2, 14). There is currently no definitive test (other than at 
autopsy) to diagnose AD, and there is no disease-modifying cure. Nowadays, the only 
treatment option is to slow the disease progression and manage the symptoms to ease 
the individual’s life. More than 95% of the cases are considered sporadic, and inherited 
cases with genetic mutations in APP, PS1, and PS2 are less than 5% (2, 10).  
 Numerous studies have proposed diverse explanations for the interaction 
between these maladies such as defects in insulin signaling, anomalous glucose 
metabolism, formation of advanced glycation end products (AGEs), oxidative stress, 
activation of inflammatory pathways, other dysregulations of cellular processes (8, 10, 
14-15), and, importantly for this study, abnormal protein processing. One of the 
important common features between T2D and AD is the presence of misfolded protein 
aggregates, which in the case of T2D consist of the accumulation in pancreas of islet 
amyloid polypeptide – (IAPP) and in AD brain (amyloid-beta - Aβ) (Fig.1) (16-17). 
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Nonetheless, T2D and AD are regarded as protein misfolding disorders (PMDs) due to 
their ability of amyloidogenesis. There are 20 more noted PMDs including Parkinson’s 
disease (PD), Prion diseases, Huntington’s disease (HD), Amyotrophic Lateral Sclerosis 
(ALS), among others. 
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Misfolded Protein Aggregates in Type II Diabetes and Alzheimer’s disease. 
 Islet amyloid polypeptide (IAPP) or amylin is a hydrophobic 37 amino acid 
peptide hormone that is secreted from the β-cells in the pancreatic islets of Langerhans. 
The islets of Langerhans function to control blood sugar levels and glucose metabolism 
throughout the body by secretion of several substances such as glucagon, insulin, 
somatostatin, and amylin. Glucagon is secreted in response to low blood sugar levels, 
and it stimulates the liver to convert glycogen into glucose. Insulin is secreted in 
response to high blood glucose levels, and it also regulates the usage of glucose - 
whether it enters the cells for energy or goes back to the liver for storage. Insulin is an 
important hormone and has multiple functions throughout the body. In the brain, studies 
have shown insulin to regulate neuronal survival, energy metabolism, plasticity of 
neurons, and growth factors (18-19). In addition, it plays a role in learning and memory 
(14, 19). Somatostatin is located in the delta cells of the islet of Langerhans and is 
known to suppress the release of gastrointestinal hormones, inhibiting the release of 
insulin and glucagon.  
IAPP is released as proislet amyloid polypeptide (proIAPP) and depends on 
blood glucose level (BGL) machinery (20-21) (Fig 2.). IAPP is co-secreted with insulin 
(1:100) from the pancreatic β-cells making insulin far more abundant. IAPP function is 
somewhat unclear, yet it is thought to contribute to glycemic control and is an inhibitor 
of the appearance of nutrients (especially glucose) in the plasma by delaying gastric 
emptying, inhibiting digestive secretion, and overall reducing food intake (giving a 
satiated feeling) (21); thus, IAPP is originated in the pancreatic β-cells and circulated 
through the blood crossing the blood-brain barrier (BBB) (21-22). IAPP has also been 
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assumed to have a role in the progression of insulin resistance in T2D patients (22). 
IAPP has been described to regulate bone metabolism and, though controversial, as an 
inhibitor of insulin, under certain conditions (22-24). As for regulation, little is known 
about the regulation of amylin synthesis, yet it is assumed since it has a close link to 
insulin being co-stored and co-secreted that it may follow the same regulatory 
mechanisms of insulin (21). Once IAPP is aggregated as a pancreatic amyloid, it is 
proposed that it contributes to the advancing decline of β-cell number and mass as well 
as later the problems with insulin secretion (4, 6, 12, 25).  As previously stated, autopsy 
reports indicate that up to 96% of T2D patients have pancreatic IAPP aggregation (7, 
9); besides humans, cats and macaques can develop T2D, and time-course studies in 
these animals showed that the accumulation of IAPP aggregates in the pancreas precede 
the symptoms of diabetes (20).  
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Figure 2. IAPP Processing. IAPP is processed from an 89-residue coding sequence
(proIAPP) that is produced in pancreatic β-cells as a 67 amino acid: (1) 11 amino acids
are removed from the N-terminal by enzyme proprotein convertase 2 (PC2); (2) 16
amino acids are removed from the C-terminal by proprotein convertase 1/3 (PC1/3); (3)
at the C-terminus carboxypeptidase E removes the lysine and arginine residues; (4)
peptidylglycine alpha-amidating monooxygenase (PAM) adds an amine group at the C-
terminal glycine.
TPIESHQVEKR KCNTATCATQRLANFLVHSSNNFGAILSSTNVGSNTYG KR NAVEVLKREPLNYLPL
PC2
PC1/3
Carboxypeptidase E
1
2
3
PAM
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The main component of Aβ plaques, a typical hallmark of AD, is a 39-43 amino 
acid polypeptide engendered by an alternative proteolytic cleavage of amyloid precursor 
protein (APP) by β-secretase 1 (BACE1) and γ-secretase leading to the formation of 
neurotoxic species (Fig. 3). Alpha secretase cleaves the ectodomain at a closer site of 
the transmembrane domain of APP producing a non-amyloidogenic, easily-cleared 
peptide known as P3; besides, BACE1 cleaves within the ectodomain producing a C-
terminal fragment substrate for γ-secretase that becomes the amyloidogenic Aβ (8, 16). 
The most deleterious Aβ form proposed is Aβ-42, but the most abundant form is Aβ-40.  
During many years, researchers focused on the insoluble Aβ fibril deposits as the 
leading cause of memory loss and neurodegeneration in AD, yet recent work has shown 
that the soluble oligomers may be the most toxic species (especially in the early stages), 
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which cause neuronal death and inhibit long term potentiation (LTP) (16-17, 26-29). Aβ 
has an unknown function, but in healthy individuals it is easily cleared from the brain 
unlike in AD affected individuals. Another hallmark of AD is the production of NFTs 
from hyperphosphorylated tau, which is a soluble microtubule associated protein 
localized within the axons and expressed in mature neurons; Aβ is known to interact 
with signaling pathways that control tau phosphorylation (2, 8, 14, 27).  
Both IAPP and Aβ can misfold and aggregate forming large and insoluble 
deposits known as amyloid. The amyloid structures have a β-sheet conformation that is 
detected by Congo Red and Thioflavin dyes, have a characteristic X-ray diffraction 
pattern, and are highly resistant to proteolytic degradation (16, 21, 27). Immunopositive 
ubiquitin staining can normally be detected in amyloid aggregates due to a failed 
attempt by the proteasome to try to clear these deleterious aggregates, which suggests 
the high resistance to proteolytic degradation of the amyloid fibrils due to their complex 
structure, being too large to fit into the protein degrading machinery, and their 
insolubility (8). IAPP and Aβ fibril-like structures also can be recognized by 
transmission electron microscopy (TEM).  
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Figure 3. Formation of Aβ through APP Cleavage. Beta secretase (BACE1) is a
transmembrane aspartyl protease that cleaves within the ectodomain of APP, leaving the
C-terminal 99-amino acid fragment (C99) containing the single transmembrane domain,
and becomes a substrate for the γ-secretase. Thus, the γ-secretase cleaves C99 at a
variable location creating an amyloidogenic protein (Aβ-40, Aβ-42) to be released to the
extracellular environment. Alpha secretase cleaves the ectodomain at a closer site of the
transmembrane domain of APP and also creates a substrate for γ-secretase producing a
non-amyloidogenic, easily-cleared peptide known as P3.
β -
secretase
α -
secretase
γ -
secretase
Aβ
Aβ
Aβ
Aβ
Aβ
p3
  
IAPP and Aβ share several characteristics, including they are both 
amyloidogenic, show 38% sequence similarity (6, 30), are directly toxic (6, 22), can 
activate proinflammatory responses as well as downstream pathways, and can alter Ca
2+
 
homeostasis by affecting downstream pathways causing cell death (31). Aβ and IAPP 
are present in blood serum and cerebrospinal fluid (CSF) (30). Potential proof of hetero-
association between Aβ and IAPP was seen when hot spot regions were identified in 
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these amyloids causing a propensity of Aβ and IAPP to interact. The results of this 
study showed that IAPP [8-18] and IAPP [22-28] sequences are hot regions of the IAPP 
and Aβ-40 interaction, and Aβ [27-32] and Aβ [35-40] were identified as the shortest 
sequences that were able to bind to IAPP with nanomolar affinity (Figure 4) (30). 
IAPP’s toxic nature was modeled by synthetic human IAPP aggregates that are able to 
induce β-cell apoptosis (12); in addition, the inhibition of IAPP accumulation or 
synthesis results in the improvement of β-cell life in a human islet culture model (12, 
25) – similarly this is noted with in vitro experiments using Aβ as well (17, 26).
Figure 4. Comparison of Sequences of Aβ and IAPP. In blue are the identical amino
acids with similar residues in green. The shortest sequences with highest similarity are
underlined in yellow. Sequences that are thought to play a role in self-association are
underlined in pink. Image taken from Andreetto E. et. al. 2010
 
The Seeding-Nucleation and Cross-Seeding Model. 
In amyloid formation it is noted the non-toxic, soluble, natively folded protein 
undergoes a conformational transition into a toxic, insoluble, and β-sheet comprising 
aggregate (32). The accumulation of misfolded aggregates (i.e. IAPP, Aβ) is thought to 
12 
 
follow a seeding-nucleation model in which a small and soluble misfolded oligomer 
(can range from dimers to decamers) acts as a nucleus to propagate misfolding by 
recruiting the native proteins into polymers (13, 16-17, 27, 33-36). In this model seen in 
Figure 5, misfolded “seeds” are produced during a nucleation or lag phase – a 
thermodynamically unfavorable stage where the folded protein changes its 
conformation to form a misfolded intermediate. The misfolded intermediate is highly 
unstable, but can be stabilized by oligomerization. When the misfolded oligomers are 
stable enough to resist clearance, the polymerization or exponential phase occurs where 
the oligomers rapidly and exponentially enlist native proteins to misfold. As a result of 
these aberrant interactions, protein aggregates have a proclivity to form large 
aggregates, become insoluble, and resistant to proteolysis, thus impervious to cellular 
clearance. Since the limiting step in this process is the formation of misfolded 
oligomeric seeds, the introduction of a pre-formed “seed” can accelerate the reaction by 
attenuating the nucleation phase (Fig. 5) (17, 33). Cross-seeding occurs when oligomers 
composed by one protein seed the aggregation of a different protein (16, 33). This 
heterologous cross-seeding has been demonstrated in vitro and in vivo involving several 
misfolded aggregates by interactions including the prion protein PrP
Sc and Aβ (37), Aβ 
and α-synuclein (38-40), Aβ and tau (35, 41-42), and others.  
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Figure 5. The Cross-Seeding Model. A) The misfolding and aggregation of proteins
follows a seeding-nucleation model in which the key event is the formation of misfolded
oligomeric seeds during the nucleation phase that acts as a scaffold building up
aggregation and forming the oligomeric and fibril species. Thus, the seed formed in this
nucleation or lag phase shortens the lag phase, and then after in the polymerization
phase, the seeds quickly and exponentially enlist inherent proteins. Moreover, protein
aggregation can be accelerated by the addition of preformed seeds. B) In some cases, the
seed can originate from a different misfolded protein, which can cross-seed the process
of protein misfolding and aggregation. Whether it is a homologous or heterologous
seeding, the nucleation phase is shortened leading to an acceleration of protein
aggregation.
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Hypothesis 
Our hypothesis is that the high coexistence of Type II diabetes and Alzheimer’s 
disease may in part be due to cross-seeding of islet amyloid polypeptide and amyloid 
beta. In this Master Thesis project, we have studied this possibility in vitro and in vivo 
in a mouse model that has been engineered to develop both IAPP and Aβ aggregates 
and analyze whether the addition of IAPP or Aβ “seeds” exacerbates the disease 
pathology of T2D and AD through pathological, immunohistochemical, and 
biochemical analysis. 
 The research presented in this dissertation is analyzing this cross-seeding 
hypothesis as a potential molecular explanation for the synergism known between T2D 
and AD. We believe that an enhancement in disease pathology could be due to a cross-
seeding effect between IAPP and Aβ and could elucidate the high co-existence of T2D 
and AD cases seen in human patients. Therefore, we will study the relationship of the 
protein aggregates IAPP and Aβ and their effect on these maladies by the following 
aims: 
1) Analyze cross-seeding interaction between Aβ and IAPP utilizing in vitro 
studies  
2) Determine the influence of Aβ aggregated “seeds” on T2D pathology in a 
double transgenic mouse model  
3) Evaluate the influence of IAPP aggregated “seeds” on AD pathology in a 
double transgenic mouse model  
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CHAPTER 2 
Analyze cross-seeding interaction between Aβ and IAPP utilizing in vitro studies 
16 
 
Rationale 
 The seeding-nucleation model states that protein misfolding and aggregation is a 
nucleation-dependent phenomenon in which a misfolded intermediate is formed during 
the lag phase and once a critical amount of these nuclei are created, the exponential 
phase starts, where the oligomeric species grow and extend producing fibrils. This 
model also states that the introduction of a preformed seed in the system is able to 
induce and accelerate protein aggregation, thus attenuating the nucleation or lag phase 
in the aggregation curve reaching the polymerization phase at a quicker rate. This can 
occur when the nuclei are of the same nature referring to homologous seeding, which 
shortens the nucleation phase. Cross-seeding or heterologous seeding occurs when the 
seeds of one particular protein accelerate the misfolding of a second particular protein. 
The resulting oligomers and fibrils will be composed by a combination of both proteins. 
Previous work has demonstrated this cross-seeding hypothesis in vitro and in vivo 
involving misfolded aggregates including the misfolded prion protein PrP
Sc and Aβ 
(37), Aβ and α-synuclein (38-40), Aβ and tau (35, 41-42), and others. The goal of this 
aim is to emulate the potential cross-seeding between Aβ and IAPP within the test tube. 
Seeding kinetic experiments will occur utilizing synthetic peptides (Aβ or IAPP) that 
will be incubated with the opposing aggregate form (so called seeds) at various 
concentrations (i.e. synthetic IAPP with purified Aβ aggregates and vice versa). 
Thioflavin T assay will be used as a method to specifically monitor the formation of 
amyloid aggregates. The ThT fluorescence originates from the dye reacting to amyloid 
fibrils (43). We expect that these in vitro studies will show cross-seeding of IAPP 
misfolding and aggregation induced by Aβ aggregates and that Aβ misfolding and 
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aggregation induced by IAPP aggregates is accelerated. We anticipate the seeds will 
shorten the nucleation or lag phase for polymerization. 
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Results 
 After running Bichinchoninic acid (BCA) assay to quantify the protein 
concentration of each IAPP and Aβ synthetic peptide and running an aggregation assay 
to check the viability of seed-free material, we began running the homologous and 
heterologous seeding for each specific protein.  
In vitro IAPP Heterologous Cross-Seeding Accelerates Aβ aggregation. 
 With IAPP and Aβ having such close sequence similarities, as well as being 
amyloidogenic, IAPP oligomeric species were used to analyze whether Aβ misfolding 
and aggregation would be accelerated due to addition of these seeds. It would be 
essential to see both homologous and heterologous seeding occur at a faster rate than 
the standard set seeding curve for Aβ by a shortening of the nucleation or lag phase. 
Utilizing the ThT assay, briefly, 10% of IAPP oligomer seeds (heterologous seeding) or 
10% Aβ oligomer seeds (homologous seeding) along with the monomeric Aβ-42 seed-
free was added to a 96 well plate; the control was an insertion of the buffer the oligomer 
was originated. The percentage of seeds corresponds to the monomeric seed-free added 
per well. The fluorescence was read by a fluorometer at excitation 435 and emission 
485 nm with intensity over time.  
First, we needed to illustrate that Aβ misfolding and aggregation is, as 
previously described, induced by homologous Aβ oligomers. In Figure 6, the results 
demonstrate a speeding up of Aβ aggregation by the shortening of the lag phase due to 
the introduction of homologous seeds compared to the control. Regarding homologous 
seeding there is an acceleration of Aβ fibrillogenesis shown by the 10% homologous Aβ 
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seeding reaching 100% aggregation at about 40 hours faster than the control, 
respectively. These results corroborate the fact that Aβ misfolding was accelerated by 
the addition of homologous Aβ seeds by attenuation of the nucleation/lag phase 
accelerating Aβ misfolding and aggregation.  
The results illustrate that the heterologous seeding of IAPP was able to reduce 
the lag phase. Figure 6 displays the heterologous seeding where there is an acceleration 
of Aβ aggregation and polymerization due to IAPP oligomeric seeds - 10% 
heterologous IAPP seeding reached 100% aggregation at about 25 hours, 10%  
homologous Aβ seeding reached 100% aggregation at about 40 hours, and the control 
reached 100% aggregation at about 72 hours, respectively. Both seeding curves were 
statistically significant from the control seeding curve. A reason that the heterologous 
IAPP seeding aggregated earlier than the homologous could be due to the higher 
amyloidogenicity of IAPP compared to Aβ allowing misfolding and accumulation to 
occur at a faster pace (44-47); in addition, the heterologous IAPP seeding could present 
more available oligomeric and/or fibrillogenic species for a faster reaction. The results 
elucidate that IAPP is an effective, viable seed for Aβ-42 aggregation by decreasing the 
lag phase for Aβ misfolding and aggregation and, thereby, inducing a faster Aβ 
aggregation. As expected, there is a cross-seeding effect in Aβ aggregation in the 
presence of IAPP oligomers.  
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Aβ Heterologous Cross-Seeding Increases IAPP aggregation In vitro. 
 Aβ-42 oligomeric seeds were used to test whether IAPP misfolding and 
aggregation would be accelerated. It would be essential to see both homologous and 
heterologous seeding occur at a faster rate than the standard set seeding curve for IAPP 
by an attenuation of the nucleation or lag phase. To analyze cross-seeding, ThT Assay 
was performed by adding 1% homologous IAPP oligomeric seeds or 1% heterologous 
Aβ oligomeric seeds, and the fluorescence read by a fluorometer at excitation 435 and 
emission 485 nm with intensity over time. One major deterrent in which several studies 
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have noted is that IAPP can essentially have a very short or even no lag phase upon 
incubation at a neutral pH, even more so with the addition of homologous seeds (44-
47). In order to confirm IAPP seeding in vitro, we needed to exemplify that IAPP 
misfolding and aggregation would be accelerated by adding homologous IAPP 
oligomers. Our results show that the homologous IAPP aggregate was able to speed up 
IAPP misfolding and aggregation, as reported before (34, 44-45, 48). Figure 7 
demonstrates an acceleration of IAPP fibrillogenesis due to the concentration of 
homologous IAPP oligomeric seeds with the 1% IAPP oligomer seeding curve reaching 
100% aggregation at about 1 hour. This evidence elucidates that IAPP does follow the 
seeding-nucleation model; IAPP aggregates are able to decline the nucleation phase, 
thus accelerating IAPP misfolding and aggregation. Following the same procedure as 
above, 1% heterologous Aβ oligomeric seeds were added to accelerate the aggregation 
reaction of IAPP. The results show that the heterologous seeding with Aβ was able to 
shorten the lag phase accelerating IAPP aggregation. Figure 7 exhibits both seedings of 
IAPP where there is an acceleration of IAPP aggregation due to heterologous or 
homologous seeds - 1% heterologous Aβ seeding reached 100% aggregation at about 4 
hours, 1% homologous IAPP seeding reached 100% aggregation at about 1 hour, and 
the control reached 100% aggregation over 13 hours, respectively. Both seeding curves 
were statistically significant from the control seeding curve. We are able to confirm that 
the addition of a seed, whether IAPP or Aβ, that there is a very short lag phase, yet the 
standard IAPP control takes hours to elevate.  
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Summary 
 In this section, we wanted to determine a cross-seeding interaction between 
IAPP and Aβ in vitro. This was done by utilizing the ThT assay incubating IAPP 
oligomeric species on synthetic Aβ-42 peptides and vice versa with different quantities 
(10 and 1%) to acquire a shortened nucleation phase from the standard seeding curve. 
Both heterologous seedings, IAPP oligomers into Aβ aggregation and Aβ oligomers 
into IAPP aggregation, demonstrated quicker kinetics by reacting to the auxiliary seed, 
by misfolding and aggregating at accelerated rates compared to the controls. Further 
work is necessary such as addition of controls - incubation with the opposing 
monomeric seed-free or incubation with a different proteins aggregate (i.e. albumin). 
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CHAPTER 3 
Determine the influence of Aβ aggregated “seeds” on T2D pathology in a double 
transgenic mouse model 
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Rationale 
After obtaining the DTg IAPP+/+/APPSwe
+/- mice expressing both human IAPP 
and human Aβ and appropriate genotypic controls - heterozygous IAPP+/-/APPSwe
+/-, 
huIAPP+/+, and huIAPP+/- on the double background- we assessed the effect of Aβ 
aggregates cross-seeding IAPP on T2D pathology (i.e. aggregation of IAPP in the 
pancreas) by analyzing the clinical symptoms and pancreatic histopathology of these 
animals. We plan to emulate what is found in affected individuals of these two PMDs – 
T2D and AD. A putative clinical symptom of T2D is hyperglycemia. We expect that the 
presence of Aβ oligomers will act as a seed increasing IAPP deposition in the β-cells. 
The augmentation of aggregated IAPP could induce β-cell death, decreasing insulin 
production and aggravating hyperglycemia in DTg animals in comparison with control 
animals. Moreover, we will analyze the difference of pancreatic amylin deposition in 
these mice by employing immunohistochemical measurements. We expect to observe 
augmented immunopositive IAPP accumulation in the pancreas as well as intensified 
BGLs in the DTg IAPP+/+/APPSwe
+/- animals to support our cross-seeding hypothesis.   
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Results 
DTg IAPP+/+/APPSwe
+/- Demonstrate Accentuated Blood Glucose Levels (BGLs). 
 In order to analyze Aβ aggregates acting as a “seed” on T2D pathology as well 
as the interaction of these associated protein aggregates, we developed DTg 
IAPP+/+/APPSwe
+/- mice that engender both IAPP and Aβ aggregates and analyzed BGLs. 
An anomalous increase of blood glucose levels is a common symptom of diabetes. The 
American Diabetes Association currently describes diabetes as having fasted blood 
glucose levels at >126 mg/dL, which is lower than the previous fasted glucose >140 
mg/dL (10, 49). Mice showing hyperglycemia are regarded having a >150 mg/dL fasted 
blood glucose levels while normal mammals are said to be <110 mg/dL (50). To analyze 
the effect of the coexistence of both amyloidogenic proteins on hyperglycemia, we 
verified the BGLs of the animals by a tail vein nick using Contour blood glucose test 
strips (Bayer Healthcare) upon sacrificing the animals at about 250 days of age to 
analyze the auxiliary effect of Aβ on this typical clinical symptom seen in T2D. Figure 
8 shows the DTg IAPP+/+/APPSwe
+/- mice had an average BGL at 171.2 mg/dL, while the 
Het IAPP+/-/APPSwe
+/- had an average of 134.27 mg/dL, IAPP+/+ of 108.67 mg/dL, and 
IAPP+/- of 100.13 mg/dL. The DTg IAPP+/+/APPSwe
+/- mice demonstrated significantly 
elevated BGLs in comparison to the control Het IAPP+/-/APPSwe
+/+, IAPP+/+, and IAPP+/-
as demonstrated by one-way ANOVA statistical analysis. The significant elevation in 
BGLs posits an exacerbation of hyperglycemia in animals harboring both Aβ and IAPP 
human proteins in comparison with animals that express just human IAPP. 
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Figure 8. DTg IAPP+/+/APPSwe+/- Demonstrate Significantly Elevated BGLs. One of
the canonical T2D pathological traits is high blood glucose levels (BGLs). The auxiliary
effect of Aβ on this typical T2D clinical symptom shows that the DTg
IAPP+/+/APPSwe+/- animals have higher BGLs than their appropriate genotypic controls.
In addition, Het IAPP+/-/APPSwe+/- have significantly higher BGLs than the IAPP+/+ and
IAPP+/-. IAPP+/+/APPSwe+/- mice show an exacerbation of hyperglycemia by displaying
an increase of BGLs in comparison to their controls. Statistical analysis was done with
GraphPad Prism 5.0; One-way ANOVA; Tukey’s: *p<0.05; ***p<0.001
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DTg IAPP+/+/APPSwe
+/- Exhibit Elevated IAPP Burden Levels. 
 To analyze whether the presence of Aβ increases the deposition of IAPP in the 
pancreas, we quantified the amount of pancreatic IAPP through immunohistochemistry, 
using an antibody that recognizes the human sequence of IAPP. As shown in Figure 9, 
the DTg IAPP+/+/APPSwe
+/- mice exhibit a higher amount of pancreatic IAPP staining 
than the controls - heterozygous IAPP+/-/APPSwe
+/- and huIAPP+/+. The DTg 
IAPP+/+/APPSwe
+/- pancreas demonstrates an intense reactivity to the human amylin 
antibody compared to controls; in addition, the areas with more intense staining likely 
correspond to protein aggregates deposited in the tissue, although at this stage we 
cannot rule out that they represent higher production of the protein. Visually, it seems 
that the IAPP accumulation occurs intracellularly and then, once when there is a 
proliferation of misfolded protein, may expel out of the cell becoming extracellular due 
to cellular death (12-13). In addition, we quantified the IAPP pancreatic burden as seen 
in Figure 10. Intriguingly; we could see that the DTg IAPP+/+/APPSwe
+/- mice exhibit a 
statistically significant increase of pancreatic amylin levels compared to their controls. 
The DTg IAPP+/+/APPSwe
+/-  had around a 1.1 fold augmentation in pancreatic IAPP 
levels compared to the Het IAPP+/-/APPSwe
+/-  as well as a 2.4 fold increase compared to 
the huIAPP+/+. Further immunohistochemical analyses by double labeling the mouse 
pancreas utilizing a permutation of antibodies with IAPP and/or different antibodies 
used for islets (i.e. insulin) may give further information about the exact cellular 
location and colocalization of various proteins (7). Thus, with the additive effect of Aβ 
being introduced as a seed, the T2D characteristics of these mice seem to be aggravated 
compared to the age-matched controls. 
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Figure 9. DTg IAPP+/+/APPSwe
+/- Exhibit Elevated IAPP Burden Levels.
Representative pictures of Langerhans islets IAPP immunostained in experimental and
control animals. DTg IAPP+/+/APPSwe+/- demonstrate augmented huIAPP pancreatic
burden as seen by immunopositive reaction to anti-huIAPP antibody compared to their
genotypic controls - heterozygous huIAPP/ APPSwe and huIAPP. Scale bar 100 um.
DTg huIAPP+/+/APPSwe
+/-
huIAPP+/+
Het huIAPP+/+/APPSwe
+/-
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Heterozygous IAPP+/-/APPSwe
+/- Mice Have T2D-like Pathology. 
 It is noted that even up to 2 years of age the regular heterozygous transgenic 
huIAPP mice have not been reported to develop any islet amyloid deposits nor any 
diabetic-like pathology, at any age (25, 51-54). However, in Figures 8 to 10, 
heterozygous IAPP+/-/APPSwe
+/-
 have a diabetic-like phenotype at 20 weeks of age, even 
greater than that of the huIAPP
+/+ mice – significantly more elevated BGLs and high 
pancreatic IAPP levels, though not significant. Thus, the seeding presence of Aβ is seen 
to bring on T2D-like phenotype in these heterozygous IAPP+/-/APPSwe
+/- which would 
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normally not be present in huIAPP+/- mice. To further verify these findings, the 
huIAPP+/- mice are planning to be immunohistochemically quantified. We expect that 
the huIAPP+/- animals will present lower amounts of pancreatic IAPP burden than the 
DTg IAPP+/+/APPSwe
+/- and Het IAPP+/-/APPSwe
+/- mice. 
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Summary 
 In this section, we investigated a T2D-like/AD mouse model, the DTg 
huIAPP+/+/APPSwe
+/-, that is able to generate both IAPP and Aβ emulating what is noted 
in human patients affected by the coexistence of these two diseases. Here, we wanted to 
determine the effect of Aβ seeds upon T2D pathology by analyzing the clinical (BGLs) 
and phenotypical (aggregation of IAPP) traits that are putatively recognized in T2D 
patients. The DTg huIAPP+/+/APPSwe
+/- had augmented BGLs compared to the 
heterozygous huIAPP+/-/APPSwe
+/- and huIAPP+/+ mice, thus emphasizing an aggravation 
of this clinical symptom. The DTg huIAPP+/+/APPSwe
+/- significantly displayed copious 
pancreatic IAPP burden levels in comparison to controls. Strikingly, the heterozygous 
huIAPP+/-/APPSwe
+/- were able to show T2D-like pathology with elevated BGLs and 
pancreatic IAPP deposition, which is normally not plausible in the huIAPP+/- mice. 
Taken together, with the elevation of both BGLs and pancreatic IAPP burden levels, the 
presence of Aβ is seen to exacerbate T2D symptoms in the DTg huIAPP+/+/APPSwe
+/- in 
comparison to the controls. 
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CHAPTER 4 
Evaluate the influence of IAPP aggregate “seeds” on AD pathology in a double 
transgenic mouse model 
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Rationale 
 Utilizing the DTg IAPP+/+/APPSwe
+/- mice expressing both human IAPP and 
human Aβ and appropriate genotypic controls - Het IAPP+/-/APPSwe
+/-, APPSwe
+/- 
injected with STZ (T1D control), and APPSwe
+/- on the double background - we assessed 
the effect of IAPP aggregates acting as a “seed” on AD pathology by analyzing 
accumulation of Aβ plaques in the brain of these animals. Analyzing 
immunohistochemically stained cortical and hippocampal slices, we expect that the co-
expression of endogenous Aβ and IAPP will cause higher Aβ plaque burden and number 
of plaques per area in comparison to controls. We analyzed the hippocampus and cortex 
due to the extensive reports of AD pathology affecting these regions in the transgenic 
mice and human patients, as well as their role in learning and memory (16, 27). We 
expect to observe augmented immunopositive Aβ accumulation in the brain in the DTg 
IAPP+/+/APPSwe
+/- animals, and a colocalization of both proteins in the brain to support 
our cross-seeding hypothesis.  
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Results 
DTg IAPP+/+/APPSwe
+/- Exhibit Increased Cortical and Hippocampal Aβ Burden 
Levels. 
 It has been established that IAPP secreted in the pancreas can cross the blood 
brain barrier and target different brain areas. We hypothesize that the presence of 
aggregated IAPP in the DTg animals will induce a higher aggregation and deposition of 
Aβ in the brain by a cross-seeding mechanism. The animals previously mentioned were 
studied to examine if there is an augmentation of AD pathology (cerebral and 
hippocampal Aβ plaques) due to the presence of IAPP aggregates. We expect to see an 
elevated Aβ plaque burden in these areas in the DTg IAPP+/+/APPSwe
+/- animals to 
confirm acceleration in pathology in comparison to the Het IAPP+/-/APPSwe
+/-, APPSwe
+/- 
injected with streptozotocin (STZ) (T1D model), and APPSwe
+/-.  
Figure 11 displays representative images of the Aβ plaques reactive to 82E1 
antibody (green). Visually we can see a difference in the size with the DTg 
IAPP+/+/APPSwe
+/- 
in comparison to the Het IAPP+/-/APPSwe
+/-, APPSwe
+/- injected with 
STZ as T1D control, and APPSwe
+/-. To prove that the augmented AD pathology is due 
to aggregated IAPP and not to the hyperglycemic environment or the reduction of 
insulin levels that also happen in the huIAPP animal model, STZ was injected into 
APPSwe
+/- acting as a T1D control.  The diabetogenic drug STZ is known to be toxic to 
the β-cells when injected and ultimately destroys them; it is thought to work by having a 
similar glucose moiety that enables STZ to enter β-cells and causes toxicity by 
alkylation of DNA (55). We are seeing that the DTg IAPP+/+/APPSwe
+/- 
animals have a 
more vigorous effect on AD pathology than STZ injected APPSwe
+/-
 animals.  
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In addition, in Figure 12 cortical and hippocampal Aβ quantifications illustrate 
that the DTg IAPP+/+/APPSwe
+/- have augmented Aβ burden in comparison to their 
genotypic controls. Moreover, the Het IAPP+/-/APPSwe
+/- have greater cortical Aβ burden 
levels compared to the APPSwe
+/-, representing a dose-dependence of the alleles. Cortical 
and hippocampal Aβ calculations were done by utilizing the percent of the area stained 
divided by the total area analyzed for Aβ load. Normally, the APPSwe
+/- or Tg2576 do 
not display AD-like pathology until a later age (56), yet the DTg IAPP+/+/APPSwe
+/- are 
demonstrating this exacerbated pathology at 250 days of age; in addition, the larger 
plaques are displayed more in the DTg IAPP+/+/APPSwe
+/- than any of the controls.  
Thus, these results indicate that the DTg IAPP+/+/APPSwe
+/- have exacerbated AD 
pathology compared AD and AD/T1D transgenic animal models, suggesting that IAPP 
“seeds” bring elevated and earlier onset of Aβ burden in comparison to the controls. 
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DTg IAPP+/+/APPSwe
+/- Reveal Increased Cortical and Hippocampal Aβ Density 
Levels. 
As noted above, the DTg IAPP+/+/APPSwe
+/-, Het IAPP+/-/APPSwe
+/-, APPSwe
+/- 
injected with STZ, and APPSwe
+/- animal groups were assessed for Aβ plaques density. 
Density refers to number of plaques per mm2 using scaled measurements in the brain. 
We expect to see an elevated Aβ plaque number in cortical and hippocampal areas in the 
DTg IAPP+/+/APPSwe
+/- animals in comparison to control groups. Figure 13 displays the 
number of plaques per mm2 in cortical with a difference in the DTg IAPP+/+/APPSwe
+/- 
in 
comparison to all controls. Moreover, for cortical density the Het IAPP+/-/APPSwe
+/- have 
greater Aβ density compared to the APPSwe
+/-. This suggests that these animals 
demonstrate a dose-dependence of the alleles. Observing the hippocampal density, the 
DTg IAPP+/+/APPSwe
+/- have more Aβ plaques per area in comparison to the APPSwe
+/- 
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injected with STZ as T1D control and APPSwe
+/-. The numbers of plaques in the DTg 
IAPP+/+/APPSwe
+/- are elevated at earlier time indicating an acceleration of the AD 
pathology; thus, these results posit that the DTg IAPP+/+/APPSwe
+/- once again have a 
more intensified AD pathology possibly due to the presence of IAPP “seeds”. 
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Colocalization of IAPP and Aβ in Cerebral Plaques in the DTg IAPP+/+/APPSwe
+/-
 
 
Very recently, it has been shown that patients affected by T2D and AD display 
brain Aβ plaques that colocalize with IAPP (57). To analyze the coexistence of both 
misfolded proteins in the brain of DTg animals, we performed a double 
immunofluoresce staining to label brain amyloid plaques using antibodies that 
recognize specifically Aβ and IAPP proteins. In our study, the DTg IAPP+/+/APPSwe
+/- 
demonstrated a colocalization between IAPP and Aβ plaques emulating what was 
recently discovered in human patients. This suggests that IAPP may directly interact 
with Aβ, acting as a seed, and increasing AD pathology. In Figure 14, immunoreactive 
IAPP to the anti-IAPP antibody is localized in fluorescent red, and the immunoreactive 
Aβ to the 82E1 anti-Aβ antibody is seen as fluorescent green. Further confirmation is 
necessary to validate this co-localization by confocal microscopy. Additionally, looking 
at Figure 15, there is also a fairly strong linear correlation with the DTg 
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IAPP+/+/APPSwe
+/- 
and the Het IAPP+/-/APPSwe
+/- 
that the more pancreatic IAPP 
deposition determines more cortical Aβ burden and vice versa (Figure 15, Pearson 
Correlation, r = 0.779). Thus, it can be posited that the more IAPP deposition in the 
mice, the more aggravation in AD pathology. This indicates that IAPP aggregates may 
directly interact by cross-seeding with Aβ and thereby exacerbate AD pathology. 
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Figure 14. Colocalization of IAPP and Aβ in Cerebral Plaques in the DTg
IAPP+/+/APPSwe
+/-. The two following representative images show a colocalization of
IAPP (red) and Aβ (green) in the brain parenchyma of the DTg IAPP+/+/APPSwe
+/-
through double immunohistochemistry. IAPP seems to be surrounded by (A) or adjacent
to (B) Aβ; nevertheless, IAPP aggregates may interact (yellow) by cross-seeding with Aβ
and thereby exacerbate AD pathology. Scale bar: 50 um (A), 100 um (B).
A
B
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Figure 15. Pancreatic IAPP Burden Correlates with Cortical Aβ Burden in
the DTg huIAPP+/+/APPSwe
+/- and Het IAPP+/-/APPSwe
+/-. This bivariate
scatterplot with regression suggests a fairly strong positive linear relationship between
pancreatic IAPP burden and cerebral Aβ burden. Thus, if one is heightened, the other is
as well. Animals with augmented levels of pancreatic IAPP will cause an increase in
cerebral Aβ burden and vice versa. Pancreatic IAPP Burden = 2.602 + 1.916 * Cortical
Aβ Burden; R2= 0.606; Pearson Correlation, r = 0.779
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Summary 
 In this section, we analyzed the effect of IAPP seeds on AD pathology through 
immunohistochemistry and quantification of cerebral Aβ plaques in the cortex and 
hippocampus of the DTg IAPP+/+/APPSwe
+/-, Het IAPP+/-/APPSwe
+/-, APPSwe
+/- injected 
with STZ (T1D) and APPSwe
+/- mice. We found that the DTg IAPP+/+/APPSwe
+/- exhibit a 
proliferation of Aβ burden levels as well as number of Aβ plaques per area in cortical 
and hippocampal tissue compared to Het IAPP+/-/APPSwe
+/-, APPSwe
+/- injected with STZ 
(T1D), and APPSwe
+/- mice.  In addition, the heterozygous IAPP+/-/APPSwe
+/- animals had 
significant cortical Aβ burden levels and Aβ density in comparison to the APPSwe
+/- 
suggesting a dose-dependence of the IAPP expression. Markedly, we were also able to 
show a colocalization of IAPP and Aβ in cerebral plaques in the DTg IAPP+/+/APPSwe
+/- 
animals corroborating with what was found in T2D-AD patients and non-diabetic AD 
patients. Analzying the DTg IAPP+/+/APPSwe
+/-and Het IAPP+/-/APPSwe
+/-, we are able to 
see a fairly strong linear correlation between pancreatic IAPP deposition and cortical Aβ 
corresponding to the more pancreatic IAPP, the more Aβ plaques, confirming that IAPP 
acting as a seed can intensify AD pathology in vivo. 
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CHAPTER 5 
Discussion 
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Cross-seeding Evidences in T2D and AD. 
With pancreatic IAPP aggregation being present in up to 96% autopsied T2D 
patients (4, 7, 11) and Aβ plaques constantly present in the brain of AD individuals, the 
importance of exploring these two amyloids cannot be stressed enough. IAPP and Aβ 
are concomitant as amyloids in PMDs yet implemented in two different diseases 
affecting disparate areas of the body. IAPP and Aβ both have the propensity to 
aggregate, have 38% sequence homology (6, 30), and induce cell death (31). 
Prominently, IAPP and Aβ follow the seeding-nucleation hypothesis, yet with the many 
similarities they have, we hypothesize that they are able to interrelate with each other 
and act as a seed to propagate protein misfolding. Our study has shown that cross-
seeding of IAPP and Aβ can occur through in vitro and in vivo methods. Within the test 
tube, we were able to show that one oligomeric species is able to diminish the 
nucleation phase, thus speeding up misfolding of the opposite monomeric species. This 
suggests that these amyloidogenic proteins are able to work both ways to assist each 
other in the start of misfolding. Our DTg IAPP+/+/APPSwe
+/- exhibited an exacerbation in 
pathology for both diseases – escalation of BGLs, significantly higher pancreatic IAPP, 
and elevated Aβ burden and density in the cortex and hippocampus.  
A plethora of supporting epidemiological and post-mortem studies exists 
relating T2D and AD in humans, yet it is not well known how one of these diseases 
could exacerbate the other malady. An epidemiological report studied almost 2,000 
individuals without mild cognitive impairment (MCI) and dementia at baseline; 
however, after a follow-up, a total of 334 individuals had some type of MCI with 
diabetes being a key player suggesting diabetes is related to a higher risk of amnestic 
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MCI in a population with an elevated prevalence of this disorder (seen in minorities) 
(60). Another studies of 65 year and older individuals noted that individuals with T2D 
were at a higher risk to develop AD (3-4, 22, 61). Our research intended to explain this 
close association between T2D and AD by a cross-seeding hypothesis, and we 
demonstrated that animals harboring both amyloidogenic proteins, Aβ and IAPP, 
showed an early onset and exacerbated development of both diseases, as demonstrated 
by increased hyperglycemia and higher misfolding protein loads. In vitro studies 
showed that there is acceleration in the aggregation ratio of one protein when the other 
misfolded protein is present in the system. These results could explain the high 
incidence of both diseases in the same individuals due to the interaction of Aβ and 
IAPP. 
Histopathological analyses also posit a role of cross-seeding between T2D and 
AD. It is reported that Aβ and tau are present in the pancreas tissue and in β-cells and 
Aβ being colocalized with IAPP in islet amyloid aggregates of T2D patients (7, 12 30, 
58). Moreover, T2D patients display increased amounts of NFTs and Aβ in the 
hippocampus (7, 14). In AD patients, there is an extensive prevalence of pancreatic 
amyloid compared to non-AD (14, 33, 58). In addition, human T2D/AD brains 
demonstrate an augmented number of cortical Aβ plaques and tau-positive cells 
compared to affected AD brains suggesting that unified T2D/AD patients have an AD 
pathology that is more severe with much more of a rapid progression (23). We have 
observed an increased amount of IAPP load in the pancreas and Aβ load in the brain of 
double transgenic animals. Indeed, the increase of both burdens is correlated. 
Furthermore, in Figure 14A, it appears that IAPP is located in the core of this plaque 
50 
 
with an Aβ “halo” surrounding the core. We know that our DTg animals do develop 
IAPP deposition first, so perhaps, IAPP could be generated in the pancreas, circulate 
through the blood crossing the BBB, and going to the brain to become our “first seed.” 
These results go along with the observations made in human tissue, indicating that the 
presence of one of the amyloidogenic proteins raises the aggregation and deposition of 
the other one, indication a possible cross-seeding effect. Recently, IAPP deposition in 
the brain was analyzed in T2D/AD patients and AD subjects. IAPP deposition was 
encountered in the blood vessels and brain parenchyma, and there was a co-localization 
between IAPP and Aβ in the cortex. This co-localization was higher in affected T2D-
AD than AD patients (57). Moreover, we were able to identify a co-localization of Aβ 
and IAPP in cerebral plaques in the double transgenic animal, very similar to what was 
described in humans.  
Relevance of Study for Novel Therapeutics 
Numerous diseases are produced by the accumulation of misfolded aggregated 
proteins including AD, prion diseases, Parkinson’s disease (PD), T2D, and more (16). 
AD and T2D are so prevalent in our society and with the quantity of elderly and 
insalubrious lifestyle of individuals increasing in our future, so too does the severity of 
these diseases. In this study, we are able to emulate in a mouse model the coexistence of 
both T2D and AD that is reported in affected humans. Moreover, cross-seeding may 
perhaps explain in part why there is a co-existence of two PMDs in a single patient in a 
higher prevalence than just by chance as well as the enhanced clinical features in some 
individuals (15, 33). Cross-seeding processes may explicate why certain disease-
affiliated protein aggregates are located in aberrant areas of the affected body (i.e. Aβ 
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colocalizing with IAPP in the pancreas and IAPP-Aβ co-localization in the brain) (33). 
These studies allow analyzing the relationship of these diseases and, therefore, aid in 
developing novel therapeutic strategies by discovering individual disease mechanisms 
by unlocking knowledge from the relationship between T2D and AD. The advantage of 
IAPP and Aβ both being amyloids and, therefore, having common structural features, 
will allow developing new therapeutic interventions to target both proteins, providing 
more effective drugs. Further information from the synergism of these diseases can 
possibly alleviate the number of both T2D and AD affected individuals, decrease the 
prevalence of both of these diseases, and ameliorate the economic burden these diseases 
place on the world. 
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CHAPTER 6 
Conclusions and Future Directions 
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Conclusions 
 In this project, we intended to explore the striking possibility of molecular 
interaction between two amyloidogenic proteins –IAPP and Aβ- through cross-seeding 
of protein misfolding by in vitro and in vivo means. We believe that an enhancement in 
disease pathology could be due to a cross-seeding effect between IAPP and Aβ and 
could elucidate the co-existence of T2D and AD cases seen in human patients (3-4, 15, 
33, 58-59). We planned to examine how each respective aggregate (Aβ or IAPP) affects 
the disparate disease pathology through in vitro aggregation assays, as well as in vivo by 
immunohistochemcial technique utilizing a novel, double transgenic mouse model that 
generates both Aβ and IAPP aggregates. Though further investigations are necessary, 
we can conclude through our preliminary results that: 
 We were able to exhibit that protein misfolding and aggregation can be 
advanced through homologous and heterologous seeding by utilizing synthetic 
peptides for both diseases where IAPP oligomeric species incubated with 
synthetic Aβ-42 and Aβ-42 oligomers incubated with synthetic IAPP were able 
to accelerate protein misfolding and aggregation. Each of these heterologous 
seeds, were able to shorten the lag phase for polymerization indicating the 
existence of a cross-seeding mechanism between Aβ and IAPP in both 
directions in vitro. 
 To determine the influence of Aβ aggregate “seeds” on T2D pathology in a 
double transgenic mouse model, the DTg IAPP+/+/APPSwe
+/- mice have 
significantly elevated BGLs in comparison to the control Het IAPP+/-/APPSwe
+/+, 
54 
 
IAPP+/+, and IAPP+/-. This indicates that the presence of Aβ peptide is able to 
aggravate T2D symptoms (hyperglycemia) in an in vivo model. 
 IAPP burden levels in the pancreas are highest in DTg IAPP+/+/APPSwe
+/-
 
animals in comparison to the Het IAPP+/-/APPSwe
+/+ and IAPP+/+ by 
immunohistochemical and quantification analysis. The heterozygous IAPP+/-
/APPSwe
+/- mice have T2D-like pathology, although heterozygous IAPP+/- do not 
develop any diabetic-like pathology at any age. Thus, the mere presence of Aβ 
peptide in the diabetic animals induces a higher deposition of IAPP in the 
pancreas confirming a possible close relationship between Aβ and IAPP 
aggregation. 
 To evaluate the influence of IAPP aggregate “seeds” on AD pathology in a 
double transgenic mouse model, the DTg IAPP+/+/APPSwe
+/- exhibit increased 
cortical and hippocampal Aβ burden levels; and Aβ plaque density compared to 
controls through Aβ immunostaining. These results indicate that the presence of 
misfolded IAPP in the brain exacerbates AD pathology in DTg animals. In 
addition, colocalization between IAPP and Aβ was seen in DTg 
IAPP+/+/APPSwe
+/- 
cerebral plaques. Moreover, there is also a fairly strong linear 
correlation with the DTg IAPP+/+/APPSwe
+/- 
and the Het IAPP+/-/APPSwe
+/- 
that 
the more pancreatic IAPP deposition determines more cortical Aβ burden and 
vice versa. This indicates that IAPP aggregates may directly interact by cross-
seed with Aβ and thereby exacerbate AD pathology.  
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Future directions 
Characterization and Quantification of In Vitro Cross-seeding. 
 Currently, after obtaining putative homologous and heterologous seeding in 
vitro assay, we plan to characterize and quantify the cross-seeding assay through use of 
immunogold labeling and TEM which will allow us to contrast the two proteins, as well 
as dot blot after fractionation and/or sedimentation assay to quantify the soluble and 
insoluble peptide for both IAPP and Aβ seeding assays. Utilizing immunogold labeling 
will result in colloidal gold particles binding to these proteins, and due to gold’s high 
electron density, it escalates electron scatter resulting in high contrast allowing us to use 
TEM to conjugate by IAPP and Aβ’s different size. For the immunogold labeling plus 
TEM, we want to prove that IAPP and Aβ are localized in the same polymer. There is 
difficulty in quantifying these assays; thus, we can attempt a sedimentation assay. 
Briefly, in the sedimentation assay, two reactive antibodies to recognize IAPP and Aβ 
will be incubated with the fractionated proteins with different time points taken in order 
to quantify the protein concentration of both proteins. In addition, further work is 
necessary such as addition of more controls - incubation with the opposing monomeric 
seed-free or incubation with a different proteins aggregate (i.e. albumin).  
  Biochemical Quantification of Amyloids in Brain and Pancreas. 
 Additionally, we will perform biochemical analysis of the brain and pancreas 
homogenates to quantify the IAPP and Aβ levels in each tissue. We will utilize enzyme-
linked immunosorbent assay (ELISA) measurements of Aβ-42 (in brain) and IAPP 
(pancreas) from the animal groups. For our case, we will use a two-step fractionation in 
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which we will centrifuge brain or pancreatic homogenate to obtain a PBS solvent 
soluble fraction that will measure soluble monomers/oligomers, and a formic acid 
solvent insoluble fraction measuring insoluble aggregates which refer to aggregated 
forms. Then, we will run brain and pancreas through both ELISAs 1) recognizing 
human Aβ and 2) recognizing human IAPP. Briefly, to make each tissue homogenate, 
mouse brain/pancreas will be weighed and calculated to add 10% of the weight/volume 
of PBS containing protease inhibitor. The brain/pancreas will be homogenized and 
frozen in liquid nitrogen and stored at -80 °C until use. Homogenate will be placed in 
Beckman centrifuge tubes and centrifuged at 32,600 rpm at 4°C for 1 hour. The PBS 
supernatant will be collected and frozen in liquid nitrogen. The insoluble pellet will be 
transferred and resuspended in formic acid solution. The sample is then sonicated to 
obtain an apt homogenous solution. After sonication, the samples are once again 
centrifuged. The formic acid fraction is collected, diluted in EC buffer, frozen in liquid 
nitrogen, and stored at -80 °C until use for ELISA quantification.  
Exogenous Cross-seeding of Aβ on T2D and IAPP on AD. 
To further investigate our cross-seeding hypothesis between in Aβ in AD and 
IAPP in T2D, we plan to exogenously induce cross-seeding in vivo by adding external 
seeds (peripherally and intracerebrally). The idea is to introduce exogenously 
heterologous IAPP seeds in Tg animals of AD (APPSwe
+/-
 or Tg2576) and Aβ seeds in 
T2D (huIAPP
+/+) and exacerbate the disease’s pathology. It has been reported that in 
vivo amyloidogenic heterologous oligomers can be injected and are able to accelerate 
the seeding process. In our laboratory, Tg2576 animals and WT littermates were 
injected intra-peritoneally (i.p.) with RML prions at 45 and 365 days old. The Tg2576 
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mice developed clear clinical signs of prion disease quicker than the non-Tg controls; in 
addition, misfolded prion protein (PrP
Sc
) formation was accelerated in prion-injected 
Tg2576, as well (33). Aβ is proven to generate AD under experimental conditions, yet 
IAPP is unknown.  Another example, amyloid beta-derived diffusible ligands (ADDLs) 
were injected into the brain and diffused throughout the brain - even in newly formed 
aggregated plaques (19, 26). Our lab has recapitulated this by injecting different tissues 
(brain, blood, pancreas), models (Tg2576, APP/PS1, huIAPP), and different proteins 
(synthetic Aβ, IAPP). In this future experiment to demonstrate the cross-seeding effect 
of Aβ on IAPP aggregates, we will take the previously described huIAPP+/+ mice and 
inject by i.p. route human AD patient or aged Tg2576 brain homogenates, as well as 
healthy human and aged non-transgenic littermates brain homogenates in huIAPP
+/+
 
mice for controls. Other control groups will likely be implemented including another 
PMD inoculum such as PD in order to see if one is a stronger seed than the other, as 
well as a non-PMD brain disease, such as hydrocephalus or schizophrenia.  The animals 
will be injected at 3 weeks of age, and the progression of a diabetes-like pathology will 
be followed overtime by taking BGL overtime; insulin resistance will be measured at 
the age of 16 weeks. The animals will be sacrificed at 20 weeks of age (Figure 16). This 
is the age when T2D pathological actions start to appear in the huIAPP
+/+
 mice; thus, we 
will be able to analyze the additive effect of exogenously introduced Aβ deposits in the 
development in T2D. The pancreatic tissue will be assayed by utilizing 
immunohistochemical and biochemical techniques. We expect to see a more robust 
acceleration of IAPP deposition in the pancreas and more severe T2D clinical signs in 
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the AD homogenate i.p. injected animals compared to the healthy homogenate injected 
animals with both human and mouse inocula. 
Figure 16. Exogenous Cross-seeding of Aβ on T2D. This figure shows the timeframe
of this experiment to introduce Aβ seeds through i.p. injection 100 μL of AD human or
aged Tg2576 in huIAPP+/+ mice (n=7/group). Animals will be injected at 3 weeks of age,
insulin resistance will be assessed at 16 weeks and will be sacrificed at 20 weeks
checking BGLs monthly overtime.
n = 7 each, huIAPP+/+ injected with AD human brain or with normal human brain
n = 7 each, huIAPP+/+ injected with aged Tg2576 brain or aged non-transgenic brain
n = 7 each, huIAPP +/+ injected with alternate PMD or non-PMD
Inject 3 weeks Sacrifice 20 weeks
Blood Glucose Levels Check Analyze pancreas
 
To demonstrate the cross-seeding effect of IAPP on AD pathology, we will 
introduce IAPP seeds exogenously by injecting human T2D pancreas or aged huIAPP
+/+
 
pancreas homogenate through intra-cerebral (i.c.) route into the previously described 
Tg2576 AD model. Tg2576 (n=7/group) will be injected at 2 months of age with either 
human: T2D pancreas, T1D pancreas, and healthy pancreas; or mouse: aged huIAPP
+/+
 
pancreas, or aged–matched WT pancreas treated with STZ (T1D), and non-diabetic WT 
59 
 
pancreas will be injected. A group of WT animals will be injected i.p. with 
Streptozotocin (STZ) to create a T1D mouse model, and the pancreas homogenate of 
these animals will be injected i.c. in order to create a Type 1 diabetic control injected 
group. This is a relevant control in that it will help elucidate the role of amylin and 
create a homogenate to be injected with a paucity of amylin without aggregates. 
Behavior will be assessed at 8.5 months by the hippocampal dependent Barnes maze, 
before any AD pathology would normally occur in these animals, and sacrificed at 9 
months (Figure 17). TopScan 2.0 tracking software will be used to track the animal’s 
movements, as well as data will be analyzed utilizing GraphPad Prism. The brain will 
be assayed by utilizing immunohistochemical and biochemical techniques to analyze 
any anomalies in the disease-like pathology of these Tg2576 animals. We expect to see 
a more robust acceleration in the T2D homogenate i.c. injected animals compared to the 
healthy homogenate and T1D induced. 
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Figure 17. Exogenous Cross-seeding of IAPP on AD and Aβ Aggregates. This figure
shows the timeframe of this experiment to introduce IAPP seeds through i.c. injection 10
μL of aged huIAPP+/+ pancreas in Tg2576 mice (n=7/group). Animals will be injected at
2 months of age and will be sacrificed at 9 months. Behavior will be assessed at 8.5
months by Barnes maze.
Inject 2 months Barnes maze 8.5 months Sacrifice 9 months
n = 7/each group, Tg2576 injected human T2D , T1D, and 
healthy pancreas
n = 7/each group, Tg2576 injected  aged huIAPP+/+, T1D, 
and non-diabetic WT mouse pancreas
Analyze brain 
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CHAPTER 7 
Materials and Methods 
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In Vitro Aβ-42 and IAPP Preparation and Aggregation. 
Aβ (1-42) synthetic peptide powder (Yale University) was dissolved (1 mg/mL) 
in 50/50 acetonitrile and water, frozen in liquid nitrogen, and lyophilized overnight. 
Next, the lyophilized Aβ was then dissolved 400 µl/mg in 10 mM NaOH (~pH 12) and 
vortexed. The high pH is away from Aβ’s isoelectric point (~pH 5.5) which will prevent 
Aβ from aggregating (62). Using a 30 KDa cut-off filter, the material was centrifuged 
for 12 min. at 14,000 X g at 4°C. This guarantees the solution will contain just be 
monomeric Aβ form, but not oligomers, so called “seed-free”. To quantify the protein 
concentration, BCA assay (Micro BCA Protein Assay, ThermoScientific) was used. 
Small aliquots were made and stored at -80 °C until use. Next, we ran an aggregation 
assay to test the quality of our Aβ seeds. Our Aβ seeds were diluted at different 
concentrations (1 μM, 2 μM, and 5 μM) in 10 mM NaOH (~pH 12) to determine the 
impeccable concentration to use for establishing a practical standard curve with an 
appropriate lag phase; thus, when we added the IAPP aggregates for the cross-seeding 
assay, we would see an acceleration in the lag phase demonstrating quicker amyloid 
accumulation compared to the standard curve. 100 µl of Tris-Cl (200 mM, pH 7.4) 
buffer was added to each well of a 96-well standard opaque plate on ice as well as 20 µg 
of monomeric Aβ-42 seed-free in each well. 10% and 1% of IAPP oligomers of the 20 
µg of Aβ-42 seed-free was added; the control was an insertion of the buffer the 
oligomer was originated with the final volume brought to 180 µl by adding sterile 
filtered water. 20 µl of 50 µM Thioflavin T (ThT) was added, and the fluorescence read 
by a fluorometer at excitation 435 and emission 485 nm with intensity over time. The 
ThT assay is a well-established in vitro staining for amyloid that recognizes and binds 
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amyloid fibrils; thus, when bound, the ThT emission peak changes allowing us to 
monitor amyloid formation (55). The plate was covered and shaken with cyclic 
agitation (500 rpm x 1 minute / no shaking 29 minutes) at 20°C while reading 
fluorescence every 24 hours or so.  
IAPP synthetic peptide powder (Yale University) was dissolved (1 mg/mL) in 
50/50 acetonitrile and water, frozen in liquid nitrogen, and lyophilized overnight. Next, 
the lyophilized IAPP was then dissolved 400 µl/mg in 2 mM HCl (~pH 2) and vortexed. 
As previously described, a 30 KDa cut-off filter was used to filter and then the material 
was centrifuged for 12 min. at 14,000 X g at 4°C. To quantify the protein concentration, 
BCA assay was used. Small aliquots were made and stored at -80 °C until use. Next, we 
ran an aggregation assay to test the quality of our IAPP seeds following the same reason 
as above – to establish a template standard curve. One deterrent is the fact that IAPP is 
known to aggregate much quicker than Aβ; thus, it would be challenging to obtain a 
standard curve with a suitable lag phase. This was accomplished by the ThT Assay was 
done by adding 8 µg of prepared IAPP seed-free and buffer per well in a 96-well 
standard opaque plate on ice in sextuplicates. 10% and 1% of Aβ oligomers from the 8 
µg of IAPP seed-free was added for the heterologous oligomeric seeds with the control 
being supplemented with the buffer the oligomer was originated (100 mM Tris-Cl). 20 
µl of 50 µM ThT was added, and the plate was covered and shaken with cyclic agitation 
(450 rpm x 1 minute / no shaking 29 minutes) at 20°C while reading fluorescence over 
time by a fluorometer at excitation 435 and emission 485 nm every hour or so. 
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In vitro Aβ and IAPP Oligomer Preparation. 
The aliquoted Aβ and IAPP seed-free peptide was diluted to a final 
concentration of 0.05 µg/µL in 100 mM Tris-Cl, pH 7.4. 400-500 µL of the diluted 
solution was placed in an Eppendorf low-binding tube and thermomixed at 25°C, 450 
rpm for 5 hours. After the 5 hours, small aliquots (20-30 μL) were made and stored at -
80°C until further use for the seeding experiments. For IAPP oligomer preparation, the 
aliquoted IAPP seed-free peptide was diluted to a final concentration of 0.04 µg/µL in 
100 mM Tris-Cl buffer. 400-500 µL of the diluted solution was placed in an Eppendorf 
low-binding tube and mixed at room temperature for 450 rpm for 90 minutes. After the 
90 minutes, small aliquots (20-30 μL) were made and stored at -80°C until further use 
for the seeding experiments. For both peptides, the concentration of oligomers was 
measured by BCA. 
Animal Models. 
The AD transgenic mouse model Tg2576 (Jackson Laboratories) are 
heterozygous animals on a S129 background over-expressing the 695 amino acid 
isoform of human APP harboring a double mutation (Lys
670Asn, Met671  Leu) 
found in a large Swedish family with early-onset AD. These animals have a 5-fold Aβ-
40 and 14-fold Aβ-42 production and have behavioral impairments and amyloid 
accumulation around 9-10 months (56). The generation and initial characterization of 
these mice has been reported previously (56). The human IAPP (huIAPP) homozygous 
transgenic mouse (Ins2-IAPP1) is a T2D animal model that over-expresses human IAPP 
on a FVB background. These animals are characterized as developing diabetic-like 
traits such as high BGLs, impaired insulin secretion, β-cell death, and aggregation of 
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IAPP at around 20 weeks of age. Important to note, the heterozygous have not been 
reported to develop islet amyloid deposits or spontaneous T2D (25). The generation and 
initial characterization of these mice has been previously reported (25). To study the 
possibility of cross-seeding of protein misfolding on the synergistic interaction between 
T2D and AD, we generated T2D/AD DTg mice by breeding these transgenic models of 
both maladies. We crossed the T2D-like huIAPP/FVB mouse with the Tg2576/S129 
AD model in which the founders gave us a set of viable heterozygotes that were then 
backcrossed with the parental homozygous transgenic huIAPP to yield a F2 generation 
of varied genetic constructs, including the DTg IAPP
+/+
/APPSwe
+/-
 model that harbors 2 
copies of human IAPP and one copy of human mutant APP. From the F2 generation, we 
also obtained the Het huIAPP
+/-
/APPSwe
+/-
, huIAPP
+/-
, and the huIAPP
+/-
 mice. The exact 
huIAPP genetic load of the DTg animals and non-transgenic littermates for controls was 
reassured by quantitative PCR (Jackson Laboratories). All groups are composed by 5-7 
animals. Since amyloid plaques start to appear around 9 months old, the transgenic 
animals were sacrificed at 8 months and 20 days to be able to analyze the acceleration 
of brain amyloidosis before their regular pattern of deposition. Before sacrificing the 
animals, BGLs were measured by a tail vein nick using Contour blood glucose test 
strips (Bayer Healthcare) after 16 hours of fasting. The animals were then sacrificed by 
CO2 inhalation and intracardially perfused with 5 μM anticoagulant 
Ethylenediaminetertraacetic acid (EDTA) PBS buffer at 250 days old extracting the 
brain and pancreas to analyze through immunohistochemistry. One half of each tissue 
was post-fixed in formalin while the other half was snap-frozen and kept at -80 °C. 
Animals were housed in groups of up to 5 in individually ventilated cages under 
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standard conditions (22 °C, 12 hour light–dark cycle) receiving food and water ad 
libitum. All animal experiments were approved by the Institutional Animal Care and 
Use Committee at The University of Texas Health Science Center in Houston Medical 
School and accordance with NIH regulations. 
Generation of STZ Injected APPSwe
+/-
 (T1D Control). 
For a T1D control we had a set of animals that develop clinical signs of diabetes 
(hyperglycemia and low insulin production by β-cell death) but without over-expression 
of human IAPP. This would prove that the augmented AD pathology is due to 
aggregated IAPP and not to the hyperglycemic environment or the reduction of insulin 
levels that also happen in the huIAPP animal model. STZ is known to be toxic to 
insulin-producing β-cells when injected and ultimately destroys them, resulting in a 
diabetic model with increased hyperglycemia. STZ (Sigma-Aldrich) was diluted in 
sodium citrate buffer (10mM, pH 4.5) and injected intraperitoneally at 110 mg/kg per 
day during two consecutive days to the overnight fasted APPSwe
+/-
. Animals were 
sacrificed at 8 months and 20 days of age. 
Immunohistochemistry (IHC). 
Brain and pancreas were removed, post-fixed into fixative solution (10% 
formalin) and embedded in paraffin. Briefly, after one week post-fixation in formalin, 
tissues were dehydrated in serial graded alcohol, immersed in xylene and embedded in 
paraffin. Serial 10 μm-thick sections from all animal groups (5 sections/stain/animal) 
were processed in parallel for immunostaining using the same solutions to minimize 
variability in staining conditions. Tissue was paraffin embedded and sliced by 
microtome mid-sagitally at 10μm. Sample slides were then deparaffinized and hydrated. 
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Briefly, slides were immersed in xylene for 15 min, in 100% ethanol, 95% ethanol, 90% 
ethanol, 80% ethanol, 70% ethanol, and dH2O for about 5 min each followed by three 
PBS for 5 min. After blocking the endogenous peroxidase activity with 3% H2O2 - 10% 
methanol in PBS, pH 7.4, for 20 min and washed, slides were incubated overnight in 
primary antibody mouse IgG anti-human Aβ 82E1 1:1000 (IBL) and/or rabbit anti-
amylin [25-37] 1:1000 (Peninsula Laboratories) in PBS Triton Buffer 0.2%. After 
washing, primary antibody was detected by incubating 1 hour at room temperature in 
PBS Triton Buffer 0.2% and Alexa Fluor 488 goat anti-mouse (to visualize Aβ) and/or 
594 goat anti-rabbit (to visualize IAPP). Finally, after washing, slides were covered 
with mounting medium with DAPI (Vector) and visualized under an epifluorescent 
microscope (DMI6000B, Leica) and analyzed in Image J software. 
Image Analysis. 
 Images were taken using a Leica DMI600 microscope at 20X objective for 
pancreas and 5X for hippocampus and cortex with threshold intensity remaining 
constant. We analyzed the hippocampus and cortex due to the extensive reports of AD 
pathology affecting chiefly these regions in transgenic mice and human patients (16, 
27). Photomicrographs were taken and imported to Image J 1.45s software and 
converted into black and white images. Pancreas and brain areas are outlined and the 
number of pixels is enumerated, and those units converted into um
2
 for quantification. 
For pancreatic IAPP burden calculations, we use the percentage of area stained to total 
area for IAPP load. In the brain, we quantify Aβ burden and Aβ plaque number and 
density. Aβ burden/load is quantified by the percentage of area stained to total area 
analyzed. Aβ plaque density is measured as how many plaques per area analyzed 
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utilizing scaled measurements. Each analysis was done by a single examiner blinded to 
sample identities. 
Statistical Analysis.  
Graphs are expressed as means ± standard error of the mean (s.e.m.). After 
confirming normal distribution with Skewness and Kurtosis statistic test, one way 
analysis of variance (ANOVA) followed by a post-hoc Tukey's multiple comparisons 
test were used to analyze differences among groups. For linear correlation, Pearson 
correlation coefficient was used. Statistical differences for all tests were considered 
significant at the p<0.05 level. Statistical analysis was performed using GraphPad Prism 
5.0 software (GraphPad Software Inc).  
  
69 
 
 
 
 
 
 
 
 
Chapter 8 
Appendix 
  
70 
 
Bibliography 
1. American Diabetes Association, 2011. National Diabetes Fact Sheet 2011. 
Diabetes Public Health Resource. Available at 
http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf, July 2012. 
2. Alzheimer’s Association. 2012 Alzheimer’s disease Facts and Figures. 
Alzheimer’s and Dementia 8 (2): 14-16 (2012). 
3. Ott A., Stolk R.P., Hofman A., van Harskamp F., Grobbee D.E., Breteler M.M. 
Association of Diabetes mellitus and dementia: the Rotterdam Study. 
Diabetologia 39: 1392-7 (1996). 
4. Ott A., Soltk R.P., van Harskamp F., Pots H.A., Hofman A., Breteler M.M. 
Diabetes mellitus and the risk of dementia: the Rotterdam Study. Neurology 53: 
1937-42 (1999). 
5. Reila R., Rodriguez B.L., Launer L.J. Type 2 Diabetes, APOE gene, and the risk 
for dementia and related pathologies: the Honolulu-Asia Aging Study. Diabetes 
51: 1256-62 (2002). 
6. Nicolls M. The Clinical and Biological Relationship between Type II Diabetes 
mellitus and Alzheimer’s disease. Current Alzheimer’s Research 1: 447-54 
(2004). 
7. Miklossy J., Qing H., Radenovic A., Kis A., Vileno B., Laszlo F., Miller L., 
Martins R.N., Waeber G., Mooser V., Bosman F., Khalili K., Darbinian N., 
McGeer P. L. Beta amyloid and hyperphosphorylated tau deposits in the pancreas 
in type 2 diabetes. Neurobiol Aging 31: 1503-1515 (2010). 
71 
 
8. Sims-Robinson C., Kim B., Rosko A., Feldman E.L. How does diabetes 
accelerate Alzheimer’s disease pathology? Nat Rev Neuro 6: 551-59 (2010). 
9. DeFronzo R. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern 
Med. 133:73–74 (2000). 
10. Luchsinger J., Gustafson D. Adiposity, type2 diabetes and Alzheimer’s 
disease. J Alzheimer’s Dis. 16(4):693-704 (2009). 
11. Clark A., de Koning E.J., Hattersley A.T., Hansen B.C., Yajnik C.S., Poulton J. 
Pancreatic pathology in non-insulin dependent diabetes (NIDDM). Diabetes Res 
Clin Pract 28: S39-47 (1995). 
12. Montane J., Klimek-Abercrombie A., Potter K.J., Westwell-Roper C., Verchere 
C.B. Metabolic Stress, IAPP, and Islet Amyloid. Diabetes, Obesity and 
Metabolism 14: 68-77 (2012). 
13. Westermark P. Amyloid in the islets of Langerhans: thoughts and some historical 
aspects. Ups J Med Sci Suppl 116: 81-89 (2011). 
14. Akter K., Lanza E.A., Martin S.A., Myronyuk N., Rua M., Raffa R.B. 
Diabetes mellitus and Alzheimer’s disease: shared pathology and treatment? 
Bri J Clin Pharmacol 71(3): 365-76 (2011). 
15. Valente T., Gella A., Fernández-Busquets X., Unzeta M., Durany N. 
Immunohistochemical analysis of human brain suggests pathological synergism 
of Alzheimer’s disease and diabetes mellitus. Neurobiol Dis 37: 67-68 (2010). 
16. Soto C. Unfolding the role of protein misfolding in neurodegenerative diseases. 
Nat Rev Neuro 4: 49-60 (2003).  
72 
 
17. Moreno-Gonzalez I., Soto C. Misfolded protein aggregates: mechanisms, 
structures, and potential for disease transmission. Sem Cell Dev Biol 22:482-487 
(2011). 
18. Chiu S.L., Chen C.M., Cline H.T. Insulin receptor signaling regulates synapse 
number, dendritic plasticity, and circuit function in vivo. Neuron 58: 708-19 
(2004). 
19. Kroner Z. The Relationship between Alzheimer’s Disease and Diabetes: Type 
3 Diabetes? Alt. Med. Review 14(4):373-77 (2009). 
20. O'Brien T.D., Butler P.C., Westermark P., Johnson K.H. Islet amyloid 
polypeptide: a review of its biology and potential roles in the pathogenesis of 
diabetes mellitus. Vet Pathol 30 (4): 317-332 (1993). 
21. Hayden M., Tyagi S.C. “A” is for Amylin and Amyloid in Type 2 Diabetes 
Mellitus. JOP 2(4): 124-139 (2001). 
22. Banks W.A., Kastin A.J., Maness L.M., Huang W., Jaspan J.B. Permeability of 
the Blood-Brain Barrier to Amylin. Life Sci 57 (22): 1993-2001 (1995). 
23. Bretherton-Watt D., Bloom S.R. Islet Amyloid Polypeptide: The Cause of 
Type-2 Diabetes? TEM 2(6): 203-207 (1991). 
24. Narita R., Toshimori H., Nakazato M., Kuribayashi T., Toshimori T., 
Kawabata K., Takahashi K., Masukura S. Islet amyloid polypeptide (IAPP) 
and pancreatic islet amyloid deposition in diabetic and non-diabetic patients. 
Diabetes Res Clin Pract 15: 3-14 (1992). 
73 
 
25. Janson J., Soeller W.C., Roche P.C., Nelson R.T., Torchia A.J., Kreutter D.K., 
Butler P.C. Spontaneous diabetes mellitus in transgenic mice expressing human 
islet amyloid polypeptide. Proc Natl Acad Sci USA 93: 7283-7288 (1996). 
26. Gaspar R.C., Villarreal S.A., Bowles N., Hepler R.W., Joyce J.G., Shughrue 
P.J. Oligomers of β-amyloid are sequestered into and seed new plaques in the 
brains of an AD mouse model.  Exp Neurol 223: 394-400 (2010). 
27. Meredith S.C. Protein Denaturation and Aggregation: Cellular Responses to 
Denatured and Aggregated Proteins. Ann N.Y. Acad Sci 1066: 181-221 
(2005). 
28. Han W., Li C. Linking type 2 diabetes and Alzheimer’s disease. Proc Natl 
Acad Sci USA 107(15):6557-58 (2010). 
29. Kimura R., MacTavish D., Yang J., Westaway D., Jhamandas J.H. Beta 
Amyloid-Induced Depression of Hippocampal Long-Term Potentiation is 
Mediated through the Amylin Receptor. J Neurosci 32(48): 17401-17406 (2012). 
30. Andreetto E., Yan L.M, Tatarek-Nossol M., Velkova A., Frank R., Kapurniotu. 
Identification of Hot Regions of the Aβ-IAPP Interaction Interface as High-
Affinity Binding Sites in both Cross-and Self-Association. Angew Chem Int Ed. 
49: 3081-85 (2010). 
31. Fu W., Ruangkittisakul A., MacTavish D., Shi J.Y., Ballanyi K., Jhamandas J.H. 
Amyloid-beta (Aβ) peptide directly activates Amylin-3 receptor subtype by 
triggering multiple intracellular signaling pathways. J Biol Chem 287 (22): 
18820-30 (2012). 
74 
 
32. Soto C., Frangione B. Two conformational states of amyloid beta-peptide: 
implications for the pathogenesis of Alzheimer's disease. Neurosci Lett 186 
(2-3): 115-118 (1995). 
33. Morales R., Moreno-Gonzalez I., Soto C. Cross-seeding of Amyloids: 
Implications in Pathogenesis and Sporadic Disease. (in press). 
34. Rochet J., Lansbury Jr. P.T. Amyloid fibrillogenesis: themes and variations. 
Curr Op in Struct Bio 10: 60-68 (2000). 
35. Jucker M., Walker L.C. Pathogenic Protein Seeding in Alzheimer’s Disease 
and Other Neurodegenerative Disorders. Ann Neurol 70(4): 532-40 (2011). 
36. Soto C., Estrada L., Catilla J. Amyloids, prions and the inherent infectious 
nature of misfolded protein aggregates. Trends Biochem Sci 31: 150-55 
(2006). 
37. Morales R., Estrada L.D., Diaz-Espinoza R., Morales-Scheining D., Jara M.C., 
Castilla J., Soto C. Molecular Cross talk between misfolded proteins in animal 
models of Alzheimer’s and prion diseases. J Neurosci 30 (13): 4528-35 (2010). 
38. Tsigelny I.F., Crews L., Desplats P., Shaked G.M., Sharikov Y., Mizuno H., 
Spencer B., Rockenstein E., Trejo M., Platoshyn O., Yuan J.X., Masliah E. 
Mechanisms of hybrid oligomer formation in the pathogenesis of combined 
Alzheimer’s and Parkinson’s diseases. PLos ONE 3 (9):e3135 (2008). 
39. Clinton L.K., Blurton-Jones M., Myczek K., Trojanowski J.Q., LaFerla F.M. 
Synergistic interactions between Abeta, tau, and alpha-synuclein: acceleration of 
neuropathology and cognitive decline. J Neurosci 30: 7281-7289 (2010). 
75 
 
40. Ono K., Takahashi R., Ikeda T., Yamada M. Cross-seeding effects of amyloid β-
protein and α-synuclein. J Neurochem 122 (5): 833-90 (2012). 
41. Gotz J., Chen F., Van Dorpe J., Nitsch R.M. Formation of neurofibrillary tangles 
in P301l tau transgenic mice induced by Abeta 42 fibrils. Science 293: 1491-
1495 (2001). 
42. Lewis J., Dickson D.W., Lin W.L., Chisholm L., Corral A., Jones G., Yen S.H., 
Sahara N., Skipper L., Vager D., Eckman C., Hardy J., Hutton M., McGowan E. 
Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau 
and APP. Science 293: 1487-1491 (2001). 
43. Biancalana M., Koide S. Molecular Mechanism of Thioflavin-T Binding to 
Amyloid Fibrils. Biochem Biophys Acta 1804(7): 1405-1412 (2010). 
44. O’Nuallain B., Williams A.D., Westermark P., Wetzel R. Seeding Specificity 
in Amyloid Growth Induced by Heterologus Fibrils. J Biol Chem 279 (17): 
17490-17499 (2004). 
45. Kayed R., Bernhagen J., Greenfield N., Sweimeh K., Brunner H., Voelter W., 
Kapurniotu A. Conformational Transitions of Islet Amyloid Polypeptide 
(IAPP) in Amyloid Formation in vitro. J Mol Biol 287: 781-796 (1999). 
46. Chargé S., de Koning E.J.P., Clark A. Effect of pH and insulin on 
fibrillogenesis of islet amyloid polypeptide in vitro. Biochem 34: 14588-
14593 (1995). 
47. Kapurniotu A., Bernhagen J., Greenfield N., Al-Abed Y., Teichberg S., Frank 
R., Voelter W., Bucala R. Contribution of advanced glycosylation to the 
76 
 
amyloidogenicity of islet amyloid polypeptide (IAPP). Eur J Biochem 251: 
208-216 (1998). 
48. Padrick S.B., Miranker A.D. Islet Amyloid: Phase Partitioning and Secondary 
Nucleation Are Central to the Mechanism of Fibrillogenesis. Bich 41: 4694-
4703 (2002). 
49. Clark M.J., Jr., Sterrett J.J., Carson D.S. Diabetes Guidelines: A Summary 
and Comparison of the Recommendations of the American Diabetes 
Association, Veterans Health Administration, and American Association of 
Clinical Endocrinologists. Clin Ther 22: 899–910 (2000). 
50. American Diabetes Association, 2012. Standards of Medical Care in Diabetes 
– 2012. Diabetes Care 35: Suppl S11-63 (2012). 
51. Fox N., Schrementi J., Nishi M., Ohagi S., Chan S.J., Heisserman J.A., 
Westermark G.T., Leckstrom A., Westermark P., Steiner D.F. Human islet 
amyloid polypeptide transgenic mice as a model of non-insulin-dependent 
diabetes mellitus (NIDDM). FEBS Lett 323: 40-44 (1993). 
52. de Koning E.J.P., Hoppener J.W.M., Verbeek J.S., Oosterwijk C., van Hulst 
K.L., Baker C.A., Lips C.J.M., Morris J.F., Clark A. Human islet amyloid 
polypeptide accumulates at similar sites in islets of transgenic mice and 
humans. Diabetes 43: 640-644 (1994). 
53. Yagui K., Yamaguchi T.,Kanatsuka A., Shimada F., Huang C.I., Tokuyama 
Y., Ohsawa  H., Yamamura K.I., Miyazaki J.I., Mikata A., Yoshida S., 
Makino H. Formation of islet amyloid fibrils in beta-secretory granules of 
77 
 
transgenic mice expressing human islet amyloid polypeptide/amylin. Eur J 
Endocrinol. 132: 487-496 (1995). 
54. Couce M., Kane L.A., O’Brien T.D., Charlesworth J., Soeller W., McNeish 
J., Kreuuter D., Roche P., Butler P.C. Treatment with growth hormone and 
dexamethasone in mice transgenic for human islet amyloid polypeptide 
causes islet amyloidosis and beta-cell dysfunction. Diabetes 45(8): 1094-101 
(1996). 
55. Tesch G.H., Allen T.J. Rodent models of streptozotocin-induced diabetic 
nephropathy. Nephrology 12: 261-266 (2007). 
56. Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., Fusheng 
Y., Cole G. Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in 
Transgenic Mice. Science 274: 99-102 (1996). 
57. Jackson K., Barisone G.A., Diaz E., Jin L., DeCarli C., Despa F. Amylin 
deposition in the brain: a second amyloid in Alzheimer’s disease? Annal of 
Neuro (in publication) (2013). 
58. Janson J., Laedtke T., Parisi J.E., O’Brien P., Peterson R.C., Butler P.C. 
Increased risk of type 2 diabetes and Alzheimer’s disease. Diabetes 53: 474-481 
(2004). 
59. Jhamandas J.H., Li Z., Westaway D., Yang J., Jassar S., MacTavish D. 
Actions of β-Amyloid Protein on Human Neurons Are Expressed through the 
Amylin Receptor. Amer J Pathol 178 (1): 140-49 (2011). 
60. Luchsinger, J.A., Reitz C., Patel B., Tang M., Manly J.J., Mayeux R. Relation of 
Diabetes to Cognitive Impairment. Arch Neurol 64(4): 570-575 (2007). 
78 
 
61. Yoshitake T., Kiyohara Y., Kato I., Ohmura T., Iwamoto H., Nakayama K., 
Ohmori S., Nomiyama K., Kawano H., Ueda K. Incidence and risk factors of 
vascular dementia and Alzheimer's disease in a defined elderly Japanese 
population: the Hisayama Study. Neurology: 45(6): 1161-8 (1995). 
62. Bitan G., Lomakin A., Teplow D.B. Amyloid-β Protein Oligomerization: 
Prenucleation Interactions Revealed by Photo-Induced Cross-Linking of 
Unmodified Proteins. J Biol Chem 276: 35176-184 (2001). 
  
79 
 
VITA 
George Edwards III, son of George Edwards, Jr. and Donna Joswiak, was born in 
Brenham, TX on August 30, 1986. He received his Associates in Science from Blinn 
College in Brenham. He obtained his Bachelors of Biology from Texas A&M 
University in College Station, TX. George worked in Dr. Jennifer Bizon and Dr. Barry 
Setlow’s laboratory at Texas A&M Psychology Department and the University of 
Florida McKnight Brain Institute for 3 years where he obtained his first publication 
(Neurobiology of Aging); in addition, he has had his work presented at over 11 national 
and international conferences. George enrolled as a graduate student at The University 
of Texas Health Science Center at Houston Graduate School of Biomedical Sciences in 
August 2011. He joined Dr. Claudio Soto’s research laboratory to carry out his 
dissertation work. 
 
 
